911 related articles for article (PubMed ID: 27859263)
21. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
22. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
[TBL] [Abstract][Full Text] [Related]
23. Differentiated rhabdomyomatous tumors after chemotherapy for metastatic testicular germ-cell tumors: a clinicopathological study of seven cases mandating separation from rhabdomyosarcoma.
Clevenger JA; Foster RS; Ulbright TM
Mod Pathol; 2009 Oct; 22(10):1361-6. PubMed ID: 19633644
[TBL] [Abstract][Full Text] [Related]
24. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
Nguyen CT; Stephenson AJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
[TBL] [Abstract][Full Text] [Related]
25. Retroperitoneal lymph node dissection after chemotherapy.
Winter C; Raman JD; Sheinfeld J; Albers P
BJU Int; 2009 Nov; 104(9 Pt B):1404-12. PubMed ID: 19840021
[TBL] [Abstract][Full Text] [Related]
26. A Machine Learning Model to Predict the Histology of Retroperitoneal Lymph Node Dissection Specimens.
Nitta S; Kojima T; Gido M; Nakagawa S; Kakeya H; Kandori S; Kawahara T; Mathis BJ; Kawai K; Negoro H; Nishiyama H
Anticancer Res; 2024 May; 44(5):2151-2157. PubMed ID: 38677742
[TBL] [Abstract][Full Text] [Related]
27. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.
Leão R; Nayan M; Punjani N; Jewett MAS; Fadaak K; Garisto J; Lewin J; Atenafu EG; Sweet J; Anson-Cartwright L; Boström P; Chung P; Warde P; Bedard PL; Bagrodia A; Freifeld Y; Power N; Winquist E; Hamilton RJ
Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550
[TBL] [Abstract][Full Text] [Related]
28. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer.
Carver BS; Cronin AM; Eggener S; Savage CJ; Motzer RJ; Bajorin D; Bosl GJ; Sheinfeld J
Urology; 2010 Jun; 75(6):1431-5. PubMed ID: 20299079
[TBL] [Abstract][Full Text] [Related]
29. Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections.
Spratt DE; Suresh K; Osawa T; Schipper M; Jackson WC; Abugharib A; Lebastchi A; Smith D; Montgomery JS; Palapattu GS; Priya Kunju L; Wu A; Lew M; Tomlins SA; Chinnaiyan AM; Weizer AZ; Hafez KS; Kaffenberger SD; Udager A; Mehra R
Med Oncol; 2018 Jan; 35(3):21. PubMed ID: 29387987
[TBL] [Abstract][Full Text] [Related]
30. Delayed orchiectomy at postchemotherapy retroperitoneal lymph node dissection due to laterality of retroperitoneal metastatic pattern consistent with testicular primary: assessment of pathologic findings.
Brown JA; Bihrle R; Foster RS
Urology; 2008 May; 71(5):911-4. PubMed ID: 18342916
[TBL] [Abstract][Full Text] [Related]
31. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.
Nicolai N; Cattaneo F; Biasoni D; Catanzaro M; Torelli T; Zazzara M; Necchi A; Giannatempo P; Raggi D; Piva L; Colecchia M; Salvioni R; Stagni S
J Endourol; 2016 Oct; 30(10):1112-1119. PubMed ID: 27533924
[TBL] [Abstract][Full Text] [Related]
32. Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study.
Miranda Ede P; Abe DK; Nesrallah AJ; dos Reis ST; Crippa A; Srougi M; Dall'Oglio MF
World J Surg Oncol; 2012 Sep; 10():203. PubMed ID: 23021209
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation.
Cary C; Pedrosa JA; Jacob J; Beck SD; Rice KR; Einhorn LH; Foster RS
Cancer; 2015 Dec; 121(24):4369-75. PubMed ID: 26371446
[TBL] [Abstract][Full Text] [Related]
34. Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting.
Considine S; Heaney R; Conroy R; Thornhill JA
Ir J Med Sci; 2016 Nov; 185(4):901-907. PubMed ID: 26692387
[TBL] [Abstract][Full Text] [Related]
35. Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project.
Klepp O; Olsson AM; Ous S; Nilsson S; Høisaether PA; Tveter K
Scand J Urol Nephrol; 1991; 25(3):179-90. PubMed ID: 1658924
[TBL] [Abstract][Full Text] [Related]
36. Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor.
Luz MA; Kotb AF; Aldousari S; Brimo F; Tanguay S; Kassouf W; Aprikian AG
World J Surg Oncol; 2010 Nov; 8():97. PubMed ID: 21062470
[TBL] [Abstract][Full Text] [Related]
37. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
38. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
[TBL] [Abstract][Full Text] [Related]
39. Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels.
Speir RW; Calaway AC; Einhorn LH; Foster RS; Cary C
Urol Oncol; 2020 Aug; 38(8):687.e19-687.e23. PubMed ID: 32448503
[TBL] [Abstract][Full Text] [Related]
40. Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.
Mano R; Becerra MF; Carver BS; Bosl GJ; Motzer RJ; Bajorin DF; Feldman DR; Sheinfeld J
J Urol; 2017 Feb; 197(2):391-397. PubMed ID: 27720783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
